b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">30846710</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>20</Day>\n        </DateRevised>\n        <Article PubModel="Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">2045-2322</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>9</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>03</Month>\n                        <Day>07</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Scientific reports</Title>\n                <ISOAbbreviation>Sci Rep</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>3788</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-019-39789-9</ELocationID>\n            <Abstract>\n                <AbstractText>Due to limited availability of pharmacological therapies, triple-negative breast cancer (TNBC) is the subtype with worst outcome. We hypothesised that 2-Deoxy-D-Glucose (2-DG), a glucose analogue, may hold potential as a therapy for particularly aggressive TNBC. We investigated 2-DG\'s effects on TNBC cell line variants, Hs578T parental cells and their isogenic more aggressive Hs578Ts(i)<sub>8</sub> variant, using migration, invasion and anoikis assays. We assessed their bioenergetics by Seahorse. We evaluated metabolic alterations using a Seahorse XF Analyzer,\xc2\xa0citrate synthase assay, immunoblotting and flow cytometry. We assessed the cancer stem cell (CSC) phenotype of the variants and 2-DG\'s effects on CSCs. 2-DG significantly inhibited migration and invasion of Hs578Ts(i)<sub>8</sub> versus Hs578T and significantly decreased their ability to resist anoikis. Investigating 2-DG\'s preferential inhibitory effect on the more aggressive cells, we found Hs578Ts(i)<sub>8</sub> also had significantly decreased oxidative phosphorylation and increased glycolysis compared to Hs578T. This is likely due to mitochondrial dysfunction in Hs578Ts(i)<sub>8</sub>, shown by their significantly decreased mitochondrial membrane potential. Furthermore, Hs578Ts(i)<sub>8</sub> had a significantly increased proportion of cells with CSC phenotype, which was significantly decreased by 2-DG. 2-DG may have benefit as a therapy for TNBC with a particularly aggressive phenotype, by targeting increased glycolysis. Studies of more cell lines and patients\' specimens are warranted.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>O\'Neill</LastName>\n                    <ForeName>Sadhbh</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Pharmacy and Pharmaceutical Sciences &amp; Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Porter</LastName>\n                    <ForeName>Richard K</ForeName>\n                    <Initials>RK</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Biochemistry and Immunology &amp; Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>McNamee</LastName>\n                    <ForeName>Niamh</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Pharmacy and Pharmaceutical Sciences &amp; Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Martinez</LastName>\n                    <ForeName>Vanesa G</ForeName>\n                    <Initials>VG</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Pharmacy and Pharmaceutical Sciences &amp; Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>O\'Driscoll</LastName>\n                    <ForeName>Lorraine</ForeName>\n                    <Initials>L</Initials>\n                    <Identifier Source="ORCID">0000-0002-9860-8262</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>School of Pharmacy and Pharmaceutical Sciences &amp; Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland. lodrisc@tcd.ie.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>07</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Sci Rep</MedlineTA>\n            <NlmUniqueID>101563288</NlmUniqueID>\n            <ISSNLinking>2045-2322</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2017</Year>\n                <Month>05</Month>\n                <Day>10</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>01</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30846710</ArticleId>\n            <ArticleId IdType="doi">10.1038/s41598-019-39789-9</ArticleId>\n            <ArticleId IdType="pii">10.1038/s41598-019-39789-9</ArticleId>\n            <ArticleId IdType="pmc">PMC6405919</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Prostate. 2010 Sep 15;70(13):1388-94</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20687211</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Sci Rep. 2017 May 11;7(1):1761</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28496098</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncogene. 1999 May 27;18(21):3199-204</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">10359525</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nature. 2005 Jul 28;436(7050):518-24</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16049480</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2014 Jul 15;74(14):3821-33</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24876102</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi56-65</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23012305</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16025097</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Leukoc Biol. 2001 Apr;69(4):522-30</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11310837</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncotarget. 2015 Oct 20;6(32):32774-89</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26416415</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Death Dis. 2013 Mar 07;4:e532</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23470539</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Cancer. 2017 Feb 28;116(5):620-625</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28152547</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Death Dis. 2014 Jul 17;5:e1336</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25032859</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Cancer. 2014 Mar 24;13:71</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24655723</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Exp Mol Pathol. 2010 Dec;89(3):372-80</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20804748</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncogene. 2013 Mar 28;32(13):1638-50</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22614004</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Chemother Pharmacol. 2013 Feb;71(2):523-30</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23228990</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Adh Migr. 2013 Sep-Oct;7(5):395-403</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24131935</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Free Radic Biol Med. 2010 Apr 15;48(8):1024-33</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20083194</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Cycle. 2013 Apr 15;12(8):1166-79</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23549172</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Stem Cell. 2011 Oct 4;9(4):357-65</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21982235</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Exp Metastasis. 2008;25(5):549-57</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18386134</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Biol Sci. 2015 Nov 01;11(12):1390-400</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26681918</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Anticancer Res. 2002 Nov-Dec;22(6A):3117-25</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12530054</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Neurochem. 2002 Jul;82(2):224-33</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12124423</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Brain Tumor Res Treat. 2013 Oct;1(2):57-63</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24904893</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Lett. 2014 Dec 28;355(2):176-83</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25218591</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Cancer. 2013 May;49(8):1845-59</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23453937</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Cell. 2003 Jun;3(6):537-49</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12842083</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>PLoS One. 2014 Nov 26;9(11):e113330</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25427064</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2006 Sep 1;66(17):8319-26</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16951136</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2003 Jul 15;63(14):3847-54</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12873971</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stem Cells. 2015 Mar;33(3):646-60</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25407338</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'